APPENDIX A

NOTICE OF VIOLATION

Rhoda H. Cobin, M.D.
Paterson, New Jersey 07514

Docket No. 030-14950
License No. 29-18376-01

As a result of the inspection conducted on June 8, 1983, and in accordance with the NRC Enforcement Policy (10 CFR 2, Appendix C), the following violations were identified:

A. 10 CFR 20.207(a) requires that licensed materials stored in an unrestricted area be secured against unauthorized removal from the place of storage. 10 CFR 20.207(b) requires that materials not in storage be under constant surveillance and immediate control of the licensee. As defined in 10 CFR 20.3(a)(17), an unrestricted area is any area access to which is not controlled by the licensee for purposes of protection of individuals from exposure to radiation and radioactive materials.

Contrary to the above, since August 21, 1981, a 223 microcurie barium-133 sealed source was not secured against unauthorized removal and was not under constant surveillance or immediate control of the licensee. At some time after August 20, 1981, the source was lost and has not been found.

This is a Severity Level IV violation (Supplement IV).

B. Condition 13 of License No. 29-18376-01 requires that sealed sources containing byproduct material be tested for leakage and/or contamination at intervals not to exceed six months.

Contrary to the above, based upon statements of the licensee, as of June 8, 1983, a sealed source containing 223 microcuries of barium-133 had not been tested for contamination or leakage since August 20, 1981, an interval of more than six months, and the licensee was not aware that the source was missing.

This is a Severity Level IV violation (Supplement VI).

C. Condition 14 of License No. 29-18376-01 requires that licensed material be possessed and used in accordance with statements, representations, and procedures contained in a letter dated January 5, 1979. Item 1 of this letter requires that all patient doses be assayed in a dose calibrator prior to administration.

Contrary to the above, based upon statements of the licensee, as of June 8, 1983, patient doses were not assayed in a dose calibrator prior to administration.

This is a Severity Level IV violation (Supplement VI).

Pursuant to the provisions of 10 CFR 2.201, Rhoda H. Cobin, M.D., is hereby required to submit to this office within thirty days of the date of the letter which transmitted this Notice, a written statement or explanation in reply, including: (1) the corrective steps which have been taken and the results achieved; (2) corrective steps which will be taken to avoid further violations; and (3) the date when full compliance will be achieved. Where good cause is shown, consideration will be given to extending this response time.